Skip to contentA
Amphastar Pharmaceuticals, Inc.
A
AMPHAmphastar Pharmaceuticals, Inc. Q1 2018 · 10-Q
Revenue$58.39M$58.39M+3.0% vs Q1 2017 Net Income-$7.14M-$7.14MN/M vs Q1 2017 EPS Diluted-$0.15-$0.15N/M vs Q1 2017 Gross Profit$16,972,000−25.6% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Amphastar Pharmaceuticals, Inc. · CIK 1297184 · Engraved from SEC EDGAR
Operating Cash Flow$8,360,000−62.7% Free Cash Flowderived-$3,980,000N/M Margins · derivedGross margin29.1%−11.2 pt vs Q1 2017
Operating margin-16.7%−19.2 pt vs Q1 2017
Net margin-12.2%−13.8 pt vs Q1 2017
ended Mar 31, 2018 · filed May 10, 2018 · 40 d after period end